StockNews.AI
COLL
StockNews.AI
117 days

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

1. COLL to report Q1 2025 financial results on May 8, 2025. 2. A live conference call will follow the earnings release. 3. Collegium focuses on growth through its ADHD treatment, Jornay PM. 4. Company aims to diversify its biopharmaceutical portfolio. 5. COLL is committed to responsible pain management solutions.

Earnings
+2.42%Current Return
VS
+2.67%S&P 500
$25.9904/24 08:08 AM EDTEvent Start
$26.6204/25 02:52 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings report can significantly influence investor sentiment and stock price. Historically, positive earnings surprises lead to price increases for pharmaceutical companies.

How important is it?

The article emphasizes an upcoming earnings call which usually has direct impact on stock pricing. Consequently, timely financial performance data can reshape investor perceptions about COLL.

Why Short Term?

The earnings report and subsequent conference call are immediate events affecting short-term stock movements. Similar past earnings seasons have resulted in swift market reactions.

Related Companies

JORN
April 24, 2025 08:00 ET  | Source: Collegium Pharmaceutical, Inc. STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event. About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com. Investor Contacts:Ian KarpHead of Investor Relationsir@collegiumpharma.com Danielle JesseDirector, Investor Relationsir@collegiumpharma.com Media Contact:Cheryl WheelerHead of Corporate Communicationscommunications@collegiumpharma.com

Related News